INCYTE CORP (INCY): Form 8-K filed 2026-11-13
- Accepted by EDGAR
- 2026-11-13 16:09 ET
- Event date
- 2026-11-13
- Accession no.
- 0000879169-26-000068
- Original filing
- SEC EDGAR filing index
AI summary of the filing text. It can contain mistakes; the original filing is authoritative.
Incyte will not proceed with planned Phase 3 MAESTRA-3 ovarian cancer study
Incyte decided not to proceed with the planned Phase 3 MAESTRA-3 study evaluating INCB123667 with bevacizumab as first-line maintenance therapy in ovarian cancer. The decision reflected clinical development portfolio prioritization, not safety or efficacy findings. Incyte does not expect an effect on its financial guidance or previously disclosed long-term outlook.
- Incyte will not proceed with the planned Phase 3 MAESTRA-3 study of INCB123667 in combination with bevacizumab.
- The study targeted first-line maintenance therapy in patients with ovarian cancer.
- The decision reflected clinical development portfolio prioritization, not safety or efficacy findings.
- Incyte does not expect the decision to affect its financial guidance or previously disclosed long-term outlook.
productguidance
Items reported
- Item 8.01: Other Events
A voluntary disclosure of an event the company considers important to security holders that no other Item covers, such as a dividend declaration, a buyback program, litigation updates or product news.
Documents
| Type | Description | Document |
|---|---|---|
| 8-K | 8-K | incy-20261113.htm |
The summary above was generated by AI from the filing text and checked automatically against it. Read the original documents on SEC EDGAR. How to read an 8-K.